title: Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
abstract: Systemic immunoglobulin light chain (LC) amyloidosis (AL) is a potentially fatal disease caused by immunoglobulin LC produced by clonal plasma cells. These LC form both toxic oligomers and amyloid deposits disrupting vital organ function. Despite reduction of LC by chemotherapy, the restoration of organ function is highly variable and often incomplete. Organ damage remains the major source of mortality and morbidity in AL. This review focuses on the challenges posed by emerging therapies that may limit the toxicity of LC and improve organ function by accelerating the resorption of amyloid deposits.
authors.affiliation: Penn Amyloidosis Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; and.
authors.forename: Brendan M
authors.identifier: 0000-0002-4448-3855
authors.initials: BM
authors.lastname: Weiss
authors.affiliation: The John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA.
authors.forename: Sandy W
authors.initials: SW
authors.lastname: Wong
authors.affiliation: The John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA.
authors.forename: Raymond L
authors.initials: RL
authors.lastname: Comenzo
mesh_terms: D000686:Amyloidosis / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000378:metabolism*; D010950:Plasma Cells / Q000378:metabolism* / Q000473:pathology
chemical_list: D007147:Immunoglobulin Light Chains